Safety and Efficacy of Sofosbuvir/Velpatasvir in Genotype 1-6 HCV-Infected Patients in China: Results from a Phase 3 Clinical Trial

被引：0

作者：

Wei, Lai ^{[1
]}

Xie, Qing ^{[2
]}

Huang, Yan ^{[3
]}

Wu, Shanming ^{[4
]}

Xu, Min ^{[5
]}

Tang, Hong ^{[6
]}

Cheng, Jun ^{[7
]}

Gao, Yanhang ^{[8
]}

Mou, Zhuangbo ^{[9
]}

Dou, Xiaoguang ^{[10
]}

Nan, Yuemin ^{[11
]}

Ning, Qin ^{[12
]}

Mao, Yimin ^{[13
]}

Stamm, Luisa ^{[14
]}

Lu, Sophia ^{[14
]}

Dvory-Sobol, Hadas ^{[14
]}

Mo, Hongmei ^{[14
]}

Brainard, Diana ^{[14
]}

Yang, Yongfeng ^{[15
]}

Wang, Guiqiang ^{[16
]}

Hu, Peng ^{[17
]}

Zhang, Lunli ^{[18
]}

Gao, Zhiliang ^{[19
]}

Lin, Feng ^{[20
]}

Shang, Jia ^{[21
]}

Gong, Guozhong ^{[22
]}

Li, Jun ^{[23
]}

Su, Minghua ^{[24
]}

Duan, Zhongping ^{[25
]}

Hou, Jinlin ^{[26
]}

Jia, Jidong ^{[27
]}

机构：

[1] Peking Univ, Peoples Hosp, Inst Hepatol, Beijing, Peoples R China

[2] Ruijin Hosp, Shanghai, Peoples R China

[3] Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China

[4] Shanghai Publ Hlth Ctr, Shanghai, Peoples R China

[5] Guangzhou Eighth Municipal Peoples Hosp, Guangzhou, Guangdong, Peoples R China

[6] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

[7] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China

[8] Jilin Univ, Hosp 1, Changchun, Jilin, Peoples R China

[9] Jinan Infect Dis Hosp, Jinan, Shandong, Peoples R China

[10] China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China

[11] Hebei Med Univ, Hosp 3, Shijiazhuang, Hebei, Peoples R China

[12] Tongji Hosp, Shanghai, Peoples R China

[13] Shanghai Renji Hosp, Shanghai, Peoples R China

[14] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[15] Second Hosp Nanjing, Nanjing, Jiangsu, Peoples R China

[16] Peking Univ, Hosp 1, Beijing, Peoples R China

[17] Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China

[18] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[19] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China

[20] Hainan Gen Hosp, Haikou, Hainan, Peoples R China

[21] Henan Prov Peoples Hosp, Zhengzhou, Henan, Peoples R China

[22] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China

[23] Nanjing Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China

[24] Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China

[25] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[26] Nanfang Hosp, Guangzhou, Guangdong, Peoples R China

[27] Beijing Friendship Hosp, Beijing, Peoples R China

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

637

引用

页码：379A / 379A

页数：1

共 50 条

[41] Efficacy and safety of ledipasvir/sofosbuvir therapy in HCV genotype 1 Korean patients
Kang, Wonseok
Sinn, Dong Hyun
Gwak, Geum-Youn
Paik, Yong-Han
Choi, Moon Seok
Lee, Joon Hyeok
Koh, Kwang Cheol
Paik, Seung Woon
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 194 - 194
[42] EFFICACY AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA AND SAFETY OF 12 WEEKS OF SOFOSBUVIR/VELPATASVIR WITH OR WITHOUT RIBAVIRIN IN GENOTYPE 3 HEPATITIS C VIRUS-INFECTED PATIENTS: A REAL-WORLD STUDY OF CHINA
Yue, Wei
Liu, Li
Xiao, An
Du, Yingrong
Gao, Jianpeng
Liu, Min
Wang, Yilan
Che, Meng
Guo, Jiaxiang
Li, Junyi
Geng, Jiawei
HEPATOLOGY, 2021, 74 : 589A - 589A
[43] An Integrated Safety and Efficacy Analysis of Sofosbuvir-Based Regimens in HCV-infected Patients with Hereditary Bleeding Disorders
Stedman, Catherine
Workowski, Kimberly
Yang, Jenny C.
Natha, Macky
Abramov, Frida
Brainard, Diana M.
Mchutchison, John G.
Balba, Gayle P.
Gane, Edward J.
Reddy, K. Rajender
HAEMOPHILIA, 2016, 22 : 22 - 22
[44] Safety and efficacy of generic daclatasvir-sofosbuvir as a pan genotypic regimen for HCV-infected patients in Bandung, Indonesia
Bestari, Muhammad Begawan
Nugraha, Eka Surya
Abdurachman, Siti Aminah
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 443 - 443
[45] Safety and Efficacy of Treatment with Sofosbuvir+GS-5816±Ribavirin for 8 or 12 Weeks in Treatment Naive Patients with Genotype 1-6 HCV Infection
Tran, Tram T.
Morgan, Timothy R.
Thuluvath, Paul J.
Etzkorn, Kyle
Hinestrosa, Federico
Tong, Myron
McNally, John
Brainard, Diana M.
Han, Lingling
Doehle, Brian
Mogalian, Erik
McHutchison, John G.
Chung, Raymond T.
Everson, Gregory T.
HEPATOLOGY, 2014, 60 : 237A - 237A
[46] Safety and Efficacy of Sofosbuvir and Ribavirin for the Treatment of HCV Genotype 2 and 3: Results of the HCV-TARGET Study
Welzel, Tania M.
Nelson, David R.
Morelli, Giuseppe
Di Bisceglie, Adrian M.
Reddy, K. Rajender
Kuo, Alexander
Lim, Joseph K.
Darling, Jama M.
Pockros, Paul J.
Galati, Joseph S.
Frazier, Lynn M.
Alqahtani, Saleh
Sulkowski, Mark S.
Fried, Michael W.
Zeuzem, Stefan
HEPATOLOGY, 2015, 62 : 727A - 728A
[47] SAFETY AND EFFICACY OF TREATMENT WITH ONCE-DAILY LEDIPASVIR/SOFOSBUVIR (90/400 MG) FOR 12 WEEKS IN GENOTYPE 1 HCV-INFECTED PATIENTS WITH SEVERE RENAL IMPAIRMENT
Lawitz, Eric
Landis, Charles S.
Maliakkal, Benedict J.
Bonacini, Maurizio
Ortiz-Lasanta, Grisell
Zhang, Jie
Mogalian, Erik
De-Oertel, Shampa
Osinusi, Anu O.
Brainard, Diana M.
McHutchison, John G.
Yip, Christina Sze Man
Huang, Hai Cheng
Flamm, Steven L.
Gordon, Stuart C.
Gane, Edward J.
GUT, 2018, 67 : A99 - A100
[48] Safety and Efficacy of Treatment with Once-Daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients with Severe Renal Impairment
Lawitz, Eric
Landis, Charles S.
Maliakkal, Benedict J.
Bonacini, Maurizio
Ortiz-Lasanta, Grisell
Zhang, Jie
Mogalian, Erik
De-Oertel, Shampa
Osinusi, Anu O.
Brainard, Diana M.
McHutchison, John G.
Flamm, Steven L.
Gordon, Stuart C.
Gane, Edward J.
HEPATOLOGY, 2017, 66 : 848A - 848A
[49] Effectiveness of Sofosbuvir/Velpatasvir for 12 Weeks in HCV Genotype 3 Patients with Compensated Cirrhosis in Clinical Practice Cohorts from Around the World
Fagiuoli, Stefano
Agarwal, Kosh
Mangia, Alessandra
Shafran, Stephen David
Wedemeyer, Heiner
Terrault, Norah
Feld, Jordan J.
Turnes, Juan
Buggisch, Peter
Ciancio, Alessia
Borgia, Sergio Marcelo
Christensen, Stefan
Vermehren, Johannes
Milligan, Scott
Matthews, Gail
Ramji, Alnoor
Pol, Stanislas
Ouzan, Denis
Wolf, John J.
Mertens, Michael
Troke, Phil
Ustianowski, Andrew
HEPATOLOGY, 2018, 68 : 360A - 361A
[50] Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients
Margusino-Framinan, Luis
Cid-Silva, Purificacion
Rotea-Salvo, Sandra
Mena-de-Cea, Alvaro
Suarez-Lopez, Francisco
Vazquez-Rodriguez, Pilar
Delgado-Blanco, Manuel
Sanclaudio-Luhia, Ana Isabel
Martin-Herranz, Isabel
Castro-Iglesias, Angeles
EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (E1) : E41 - E47

← 1 2 3 4 5 →